H19 and ovarian cancer: In this study, miR-675-3p expression was not associated with RFS in ovarian cancer patients, and the expression of miR-675-3p was not affected by H19 knockdown, indicating that H19 involvement in cisplatin resistance is not related to miR-675-3p.